雅思阅读Listofheadings题型解题技巧详解

雅思阅读Listofheadings题型解题

技巧详解

雅思阅读一直以来List of headings 题型都是大家失分较为严重的题型，今天给大家带来了List of headings题型解题技巧详解，希望能帮助到大家，下面就和大家分享，来欣赏一下吧。

【雅思阅读技巧】List of headings题型解题技巧详解

答题技巧：

1. 首先在list of headings中划去做为例子的heading 或headings，以免在根据段落内容在list of headings中找出与其相匹配的段落标题时，它(它们)会干扰考试者对其他headings的选择。

2. 在*中把做为例子的段落划掉，以免对例子段落进行不必要的精读。

3. 对题目中给出的段落，按照首句(第一、二句)、末句和中间句寻找主题句的顺序的方法，读完段落再读list，在list of headings中找出与其相匹配的段落标题。但是注意，近年来雅思出题有一个趋势，list of headings的题目只有极少数情况下是在

首尾有总结句，大部分情况还是需要考生通读全段，总结后对比headings来选择。

4. 如果某一个list of headings选项与原文一模一样，完全没有差别的，这个一般不是正确答案，list of headings的题目都是需要稍微归纳得出的。

5. 对于不确定的答案的段落稍微放一放，把确定答案的题目选出来后，利用排除法，选出最贴近段落大意的。

6. 注意段落中复杂长句子的表意重点，一般来说，however，but，but also, although, despite这类词的后面是句子的重点。举例的句子可以略过，一般不会影响答案的选择。

7. 要仔细检察答案，特别是第一题型，因为答错一题，就意味着答错两道题。

8. 切忌过度推理，headings有时候会出现原文中只有部分表述的内容，用来干扰考生。

雅思考试阅读模拟试题及答案解析

1. The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels. But many researchers remain confident that drugs to boost levels of ’good’ cholesterol are still one of the most promising means to combat spiralling heart disease.

2. Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib，a drug designed to raise heart-protective high-density lipoproteins (HDLs)。In a trial of 15000 patients，a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone.

3. The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease. “There have been no red flags to my knowledge，” says John Chapman，a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib. “This cancellation came as a complete shock.”

4. Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs，which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body. Specifically，torcetrapib blocks a protein called cholesterol ester transfer protein (CETP)，which normally transfers the cholesterol from high-density lipoproteins to low density，plaque-promoting

ones. Statins，in contrast，mainly work by lowering the ’bad’ low-density lipoproteins.

Under pressure

5. Researchers are now trying to work out why and how the drug backfired，something that will not become clear until the clinical details are released by Pfizer. One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients. It was thought that this mild problem would be offset by the heart benefits of the drug. But it is possible that it actually proved fatal in some patients who already suffered high blood pressure. If blood pressure is the explanation，it would actually be good news for drug developers because it suggests that the problems are specific to this compound. Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall.

6. But it is also possible that the whole idea of blocking CETP is flawed，says Moti Kashyap，who directs atherosclerosis research at the VA Medical Center in Long Beach，California. When HDLs excrete cholesterol in the liver，they actually rely on LDLs for part of this process. So inhibiting CETP，which prevents the transfer of cholesterol from HDL to LDL，might actually cause an abnormal